Denali Therapeutics Inc. $DNLI Stake Reduced by Yiheng Capital Management L.P.

Key Points

• Yiheng Capital Management L.P. reduced its holdings in Denali Therapeutics by 32.9%, selling 230,117 shares and leaving it as the fund's 13th largest holding, now worth approximately $6.39 million.
• CEO Ryan J. Watts sold 495,282 shares at an average price of $15.00, significantly decreasing his position by 66.18%, while insiders collectively sold over 501,962 shares in recent months.
• Denali Therapeutics reported a quarterly EPS of ($0.72), surpassing analysts’ expectations, and currently has an average analyst rating of "Buy" with a target price of $33.62.

Yiheng Capital Management L.P. decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 469,981 shares of the company's stock after selling 230,117 shares during the quarter. Denali Therapeutics comprises approximately 0.4% of Yiheng Capital Management L.P.'s portfolio, making the stock its 13th biggest holding. Yiheng Capital Management L.P. owned about 0.32% of Denali Therapeutics worth $6,389,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Denali Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock valued at $548,000 after acquiring an additional 1,058 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after acquiring an additional 1,551 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Denali Therapeutics by 0.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock worth $4,250,000 after buying an additional 1,702 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics by 20.7% in the 1st quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company's stock worth $164,000 after buying an additional 2,072 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Denali Therapeutics in the 1st quarter worth about $41,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Activity

In other news, insider Carole Ho sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. The trade was a 1.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider owned 242,346 shares of the company's stock, valued at $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is currently owned by insiders.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded down $0.47 during trading on Thursday, reaching $14.84. The stock had a trading volume of 294,555 shares, compared to its average volume of 1,451,958. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The stock has a market cap of $2.17 billion, a PE ratio of -5.30 and a beta of 1.23. The firm's 50 day moving average price is $14.52 and its two-hundred day moving average price is $14.74.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same period in the prior year, the company earned ($0.59) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Robert W. Baird reduced their price objective on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Wedbush reduced their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reduced their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. TD Cowen raised Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Finally, Morgan Stanley reduced their price target on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, August 18th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.